{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:22:20Z","timestamp":1792790540780,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T00:00:00Z","timestamp":1580083200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T00:00:00Z","timestamp":1580083200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["K12 GM093854"],"award-info":[{"award-number":["K12 GM093854"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["HL118414"],"award-info":[{"award-number":["HL118414"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R21 DA043983"],"award-info":[{"award-number":["R21 DA043983"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"},{"id":"https:\/\/ror.org\/05p26gw61","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01 DA006214"],"award-info":[{"award-number":["R01 DA006214"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"},{"id":"https:\/\/ror.org\/05p26gw61","id-type":"ROR","asserted-by":"crossref"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","id":[{"id":"https:\/\/ror.org\/05p26gw61","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1038\/s41386-020-0619-x","type":"journal-article","created":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T05:04:14Z","timestamp":1580101454000},"page":"717-719","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Repurposing the dual orexin receptor antagonist suvorexant for the treatment of opioid use disorder: why sleep on this any longer?"],"prefix":"10.1038","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9298-8607","authenticated-orcid":false,"given":"Morgan H.","family":"James","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer E.","family":"Fragale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Nisha","family":"Aurora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina A.","family":"Cooperman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel D.","family":"Langleben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Aston-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,27]]},"reference":[{"key":"619_CR1","doi-asserted-by":"publisher","unstructured":"Rasmussen K, White DA, Acri JB. NIDA\u2019s medication development priorities in response to the opioid crisis: ten most wanted. Neuropsychopharmacology. 2018. https:\/\/doi.org\/10.1038\/s41386-018-0292-5.","DOI":"10.1038\/s41386-018-0292-5"},{"key":"619_CR2","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/7854_2016_57","volume":"33","author":"MH James","year":"2017","unstructured":"James MH, Mahler SV, Moorman DE, Aston-Jones G. A decade of orexin\/hypocretin and addiction: where are we now? Curr Top Behav Neurosci. 2017;33:247\u201381.","journal-title":"Curr Top Behav Neurosci"},{"key":"619_CR3","doi-asserted-by":"publisher","unstructured":"Campbell EJ, Marchant NJ, Lawrence AJ. A sleeping giant: suvorexant for the treatment of alcohol use disorder? Brain Res. 2018. https:\/\/doi.org\/10.1016\/j.brainres.2018.08.005.","DOI":"10.1016\/j.brainres.2018.08.005"},{"key":"619_CR4","doi-asserted-by":"crossref","unstructured":"James MH, Aston-Jones G. Introduction to the Special Issue: \u201cOrexin\/hypocretin receptor antagonists for the treatment of addiction and related psychiatric disease: What are the steps from here?\u201d. Brain Res. 2020:146665.","DOI":"10.1016\/j.brainres.2020.146665"},{"key":"619_CR5","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1016\/j.addbeh.2014.05.025","volume":"39","author":"EE Hartwell","year":"2014","unstructured":"Hartwell EE, Pfeifer JG, McCauley JL, Moran-Santa Maria M, Back SE. Sleep disturbances and pain among individuals with prescription opioid dependence. Addict Behav. 2014;39:1537\u201342.","journal-title":"Addict Behav"},{"key":"619_CR6","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/7854_2016_56","volume":"33","author":"MH James","year":"2017","unstructured":"James MH, Campbell EJ, Dayas CV. Role of the orexin\/hypocretin system in stress-related psychiatric disorders. Curr Top Behav Neurosci. 2017;33:197\u2013219.","journal-title":"Curr Top Behav Neurosci"},{"key":"619_CR7","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.1523\/JNEUROSCI.23-08-03106.2003","volume":"23","author":"D Georgescu","year":"2003","unstructured":"Georgescu D, Zachariou V, Barrot M, Mieda M, Willie JT, Eisch AJ, et al. Involvement of the lateral hypothalamic peptide orexin in morphine dependence and withdrawal. J Neurosci. 2003;23:3106\u201311.","journal-title":"J Neurosci"},{"key":"619_CR8","doi-asserted-by":"publisher","unstructured":"Simmons SJ, Gentile TA. Cocaine abuse and midbrain circuits: functional anatomy of hypocretin\/orexin transmission and therapeutic prospect. Brain Res. 2019. https:\/\/doi.org\/10.1016\/j.brainres.2019.02.026.","DOI":"10.1016\/j.brainres.2019.02.026"},{"key":"619_CR9","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1038\/s41386-019-0420-x","volume":"44","author":"JE Fragale","year":"2019","unstructured":"Fragale JE, Pantazis CB, James MH, Aston-Jones G. The role of orexin-1 receptor signaling in demand for the opioid fentanyl. Neuropsychopharmacology. 2019;44:1690\u20137.","journal-title":"Neuropsychopharmacology"},{"key":"619_CR10","doi-asserted-by":"publisher","first-page":"5320","DOI":"10.1021\/jm100541c","volume":"53","author":"CD Cox","year":"2010","unstructured":"Cox CD, Breslin MJ, Whitman DB, Schreier JD, McGaughey GB, Bogusky MJ. et al. Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl]\u2009[5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia. J Med Chem. 2010;53:5320\u201332.","journal-title":"J Med Chem"},{"key":"619_CR11","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/npp.2014.293","volume":"40","author":"BE Schmeichel","year":"2015","unstructured":"Schmeichel BE, Barbier E, Misra KK, Contet C, Schlosburg JE, Grigoriadis D, et al. Hypocretin receptor 2 antagonism dose-dependently reduces escalated heroin self-administration in rats. Neuropsychopharmacology. 2015;40:1123\u20139.","journal-title":"Neuropsychopharmacology"},{"key":"619_CR12","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.neuropharm.2012.07.044","volume":"63","author":"L Zhou","year":"2012","unstructured":"Zhou L, Smith RJ, Do PH, Aston-Jones G, See RE. Repeated orexin 1 receptor antagonism effects on cocaine seeking in rats. Neuropharmacology. 2012;63:1201\u20137.","journal-title":"Neuropharmacology"},{"key":"619_CR13","doi-asserted-by":"publisher","unstructured":"Mohammadkhani A, James MH, Aston-Jones G. Persistent effects of the orexin-1 receptor antagonist SB-334867 on motivation for the fast acting opioid remifentanil. Brain Res. 2019:146461. https:\/\/doi.org\/10.1016\/j.brainres.2019.146461.","DOI":"10.1016\/j.brainres.2019.146461"},{"key":"619_CR14","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.5665\/sleep.5168","volume":"38","author":"A Vermeeren","year":"2015","unstructured":"Vermeeren A, Sun H, Vuurman EF, Jongen S, Van Leeuwen CJ, Van Oers AC, et al. On-the-road driving performance the morning after bedtime use of suvorexant 20 and 40 mg: a study in non-elderly healthy volunteers. Sleep. 2015;38:1803\u201313.","journal-title":"Sleep"},{"key":"619_CR15","doi-asserted-by":"publisher","unstructured":"James MH, Bowrey HE, Stopper CM, Aston-Jones G. Demand elasticity predicts addiction endophenotypes and the therapeutic efficacy of an orexin\/hypocretin-1 receptor antagonist in rats. Eur J Neurosci. 2018. https:\/\/doi.org\/10.1111\/ejn.14166.","DOI":"10.1111\/ejn.14166"},{"key":"619_CR16","doi-asserted-by":"publisher","first-page":"7295","DOI":"10.1523\/JNEUROSCI.4385-14.2015","volume":"35","author":"C Baimel","year":"2015","unstructured":"Baimel C, Borgland SL. Orexin signaling in the VTA gates morphine-induced synaptic plasticity. J Neurosci. 2015;35:7295\u2013303.","journal-title":"J Neurosci"},{"key":"619_CR17","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1126\/science.1683005","volume":"254","author":"JC Smith","year":"1991","unstructured":"Smith JC, Ellenberger HH, Ballanyi K, Richter DW, Feldman JL. Pre-Botzinger complex: a brainstem region that may generate respiratory rhythm in mammals. Science. 1991;254:726\u20139.","journal-title":"Science"},{"key":"619_CR18","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/7854_2016_46","volume":"33","author":"P Carrive","year":"2017","unstructured":"Carrive P, Kuwaki T. Orexin and central modulation of cardiovascular and respiratory function. Curr Top Behav Neurosci. 2017;33:157\u201396.","journal-title":"Curr Top Behav Neurosci"},{"key":"619_CR19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(99)05582-8","volume":"355","author":"S Nishino","year":"2000","unstructured":"Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet. 2000;355:39\u201340.","journal-title":"Lancet"},{"key":"619_CR20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.5664\/jcsm.5382","volume":"12","author":"H Sun","year":"2016","unstructured":"Sun H, Palcza J, Card D, Gipson A, Rosenberg R, Kryger M, et al. Effects of suvorexant, an orexin receptor antagonist, on respiration during sleep in patients with obstructive sleep apnea. J Clin Sleep Med. 2016;12:9\u201317.","journal-title":"J Clin Sleep Med"},{"key":"619_CR21","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.yrtph.2017.03.006","volume":"86","author":"S Born","year":"2017","unstructured":"Born S, Gauvin DV, Mukherjee S, Briscoe R. Preclinical assessment of the abuse potential of the orexin receptor antagonist, suvorexant. Regul Toxicol Pharmacol. 2017;86:181\u201392.","journal-title":"Regul Toxicol Pharmacol"},{"key":"619_CR22","doi-asserted-by":"publisher","unstructured":"Suchting R, Yoon JH, Miguel GGS, Green CE, Weaver MF, Vincent JN, et al. Preliminary examination of the orexin system on relapse-related factors in cocaine use disorder. Brain Res. 2019. https:\/\/doi.org\/10.1016\/j.brainres.2019.146359.","DOI":"10.1016\/j.brainres.2019.146359"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41386-020-0619-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41386-020-0619-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41386-020-0619-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:08:21Z","timestamp":1684602501000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-020-0619-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,27]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["619"],"URL":"https:\/\/doi.org\/10.1038\/s41386-020-0619-x","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,27]]},"assertion":[{"value":"25 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}